In the present study, the anti-HCC effect of combined therapy with Ad-ΔB/TRAIL+Ad-ΔB/IL-12 were measured both in vitro on human Hep3B and HuH7 cell lines; which are well differentiated human hepatocyte-derived cellular carcinoma cell lines commonly used in studying liver cancer and its potential therapies [32, 36], and in vivo on an orthotopic model of human HCC established by intrahepatic implantation of Hep3B into the liver lobes of immunodeficient nude mice. The gene discussed is TNFSF10; the disease is liver cancer.